Impact of Computer-Generated Personalized Goals on Cholesterol Lowering  by Levetan, Claresa S. et al.
Volume 8 • Number 6 • 2005
V A L U E  I N  H E A L T H
© ISPOR 1098-3015/05/639 639–646 639
10.1111/j.1524-4733.2005.00057.x
Blackwell Science, LtdOxford, UKVHEValue in Health1098-30152005 ISPOR86639646Original ArticleImpact of Computer-Generated Goals on CholesterolLevetan et al.
Address correspondence to: Claresa S. Levetan, 100 Lancas-
ter Avenue, Suite 222 South MOB, Wynnewood, PA 19096,
USA. E-mail: levetan@juno.com
Impact of Computer-Generated Personalized Goals on 
Cholesterol Lowering
Claresa S. Levetan, MD,1 Karen R. Dawn, RN, CDE,1 James F. Murray, PhD,2 Jeffrey J. Popma, MD,3 
Robert E. Ratner, MD,4 David C. Robbins, MD5
1Department of Internal Medicine, Lankenau Hospital, Wynnewood, PA, USA; 2Division of Outcomes Research and Biostatistics, Merck, 
Inc. West Point, PA, USA; 3Department of Internal Medicine (Cardiology Division), Brigham and Women’s Hospital, Boston, MA, USA; 
4MedStar Research Institute, Washington DC, USA; 5Lilly and Company, Indianapolis, IN, USA
ABSTRACT
Objectives: The National Cholesterol Education Pro-
gram (NCEP) has enhanced public awareness of the
importance of cholesterol in the development of heart dis-
ease, yet most patients with cardiovascular disease (CVD)
do not know or achieve their low-density lipoprotein cho-
lesterol (LDL-C) goals. This randomized, controlled trial
was designed to evaluate the impact of a system that pro-
vides uniquely formatted laboratory results to patients
with CVD on their changes in LDL-C levels.
Methods: Eighty patients with CVD were randomized to
receive standard care or the intervention inclusive of a
computer-generated, 11≤ ¥ 17≤ color poster depicting an
individual’s LDL-C status and goals along with personal-
ized steps to aid in goal achievement. Cholesterol proﬁles
were obtained at baseline and 6 months after enrollment.
Physicians received standard laboratory reports and were
blinded to the randomization.
Results: There were no signiﬁcant differences between
patient groups in age, education level, race, baseline
cholesterol levels, comorbidities, or percentage of patients
in each group who met their NCEP goal at baseline.
Patients receiving intervention tools had signiﬁcant reduc-
tions in LDL-C from baseline compared with patients in
the control group. Intervention patients who did not meet
NCEP goals at baseline had the greatest reduction in
LDL-C, with a mean change from baseline of -21.5 mg/
dL (P < 0.001) whereas standard care patients had no
signiﬁcant change in the LDL-C levels (-4.6 mg/dL,
P = 0.28). At study close, 73% of intervention patients
reported that their posters remained displayed on their
refrigerator.
Conclusion: This unique and personalized interven-
tion resulted in the LDL-C lowering beneﬁt among
patients with CVD comparable to that of lipid lower-
ing agents.
Keywords: coronary prevention, novel approaches,
patient awareness
Introduction
Written goals and objectives lay the foundation for
achieving success in most disciplines including busi-
ness, science and education. Written contracts
between health educators and patients have resulted
in improved outcomes by shifting the locus of con-
trol from the health-care provider to the patient
[1,2]. These principles have not typically been
incorporated into medical school curricula, nor are
physicians exposed to innovative modes of commu-
nication that may aid patients in achieving their
health goals. For example, persons who know their
health goals and believe that these goals are within
their control are more likely to have improved out-
comes and engage in self-care behaviors including
exercise and weight loss programs [1–13].
Because physicians have less time to see more
patients, and preventive services are almost nonex-
istent in most practices, creative solutions are
required to address the realities of modern health
care. Numerous studies underscore the opportuni-
ties missed by physicians for providing preventive
cardiovascular counseling and optimizing lipid-low-
ering medications [14–21]. For example, cardiolo-
gists perceived a heightened awareness of the
importance of National Cholesterol Education Pro-
gram (NCEP) guidelines and claimed aggressive
cholesterol screening and treatment, yet this was
not borne out in their practices [22]. Headrick and
colleagues evaluated a variety of educational inter-
ventions for physicians, and found that all had a
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limited impact on improving physician compliance
to the guidelines set forth by the NCEP.
Currently, less than 15% of patients with cardi-
ovascular disease (CVD) met their NCEP goals and
more than half received no dietary counseling or
cholesterol-lowering medication [16]. Avorn and
other researchers have valuated how best to deliver
messages and feedback to patients regarding their
cholesterol goals. Studies have included tailored let-
ters, computerized telephony messages, individual-
ized and group educational sessions, yet, there are
no standardized methods for delivering effective
messages to patients about their cholesterol status
and goals [23–27]. We designed a computer pro-
gram that produces a unique format for providing
patients with their own cholesterol status, goals and
steps to meet their goal. We set forth to evaluate
whether these customized written goals might facil-
itate low-density lipoprotein cholesterol (LDL-C)
lowering without directly involving the physician
among a in high-risk patients with CVD by provid-
ing a daily visual reminder for patients and their
families.
Patients and Methods
Patients
We receiving approval from The Washington Hos-
pital Center’s Institutional Review Board, which
included approval of an informed consent form to
be signed by all patients to be enrolled in this study.
We identiﬁed hospitalized patients with docu-
mented CVD on the cardiology service at The
Washington Hospital Center (a 907-bed, tertiary
care teaching hospital) between February 1, 1998
and April 31, 1998. Patients with a history of dia-
betes were not enrolled to eliminate metabolic
parameters that may impact lipids. Patients who
could not read were excluded from the study.
Patients who had already received a transfusion
during their hospital stay or were being evaluated
for acute myocardial infarction were excluded to
prevent spurious results, and those with an under-
lying illness, such as malignancy, which was
expected to impact their survival over the following
6 months, were excluded from enrollment.
Study Design
All patients were told they were entering an educa-
tional study designed to evaluate the impact of cho-
lesterol educational tools on outcomes. Patients
who met enrollment criteria and agreed to partici-
pate were asked to read and sign informed consent.
A nurse obtained baseline demographic data,
weight, blood pressure, a list of current medica-
tions, and a fasting lipid proﬁle on all patients. A
brief patient questionnaire was completed on all
participants and included patient report of dietary,
exercise and smoking habits.
The questionnaire provided multiple options and
participants were asked to select the one best
option. Included in the questionnaire was their
knowledge of the names for and the difference
between the “good” and “bad” cholesterol. At
enrollment, all patients who did not know the dif-
ference between the LDL-C and high-density lipo-
protein cholesterol (HDL-C) were informed. After
the initial interview, patients were randomly
assigned to receive standard care or the experimen-
tal intervention. One hundred cards were randomly
assigned to either the intervention or control group
and placed in sealed envelopes that were numbered
from 1 to 100.
Physicians providing care to both groups
received the standard laboratory reporting form
with the results of the lipid proﬁle. The results of the
lipid proﬁle were also mailed to the patient’s physi-
cian(s) providing medical care after hospitalization.
Laboratory results were available within 1 week of
initial enrollment. Baseline LDL-C level was not a
study exclusion. Physicians did not receive any of
the intervention materials, and were blinded to
which of their patients were receiving the active
intervention.
Standard  care  (control). Patients in the control
group received usual healthcare advice provided by
the hospital, which included hospital discharge
materials on cardiovascular health and any addi-
tional information provided by their physician.
Patients in the standard care group did not receive a
personalized report, follow-up phone call or
monthly postcards.
Intervention. Each patient in the intervention
group received a computer-generated customized
report presented as an 11≤ ¥ 17≤ laminated color
poster backed with magnets that graphically
depicted their LDL-C, HDL-C, blood pressure, and
weight status along with a bulleted list of personal-
ized goals and steps necessary for achievement of
the goals (Fig. 1). This was sent by mail immedi-
ately after their hospital discharge. Based on the
responses to a one-page questionnaire including
self-reported diet and exercise habits and the
patient’s laboratory data, the individual’s report
was generated from an Microsoft Access97-based
decision support system that collected patient infor-
mation from the enrollment questionnaire and
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Figure 1 Personalized 11≤ ¥ 17≤ empower-
ment poster, laminated and backed with mag-
nets for patients to place on their refrigerator.
matched it against a knowledge base of established
diabetes, cardiovascular, nutrition and exercise
guidelines.
Patients also received a personalized wallet card
that included their baseline lipid and blood pres-
sure status, with room to document subsequent
values. One postcard per month was sent to each
patient for the duration of the study, which
emphasized the relationship between LDL-C and
atherosclerosis and provided an action step for
LDL-C lowering.
The computer program utilized a relational data
decision support system that collected patient infor-
mation and matched it against a knowledge base of
established cardiovascular, nutrition, and exercise
guidelines. Greater than 10,000 possible options for
each poster’s action plan were possible. There was
no subjective interpretation from the personal inter-
view, but the questionnaire asked participants to
provide the names of family members, pets or
friends who exercise, cook or share time with the
participant, and these names were included in the
personalized reports.
The posters included bulleted points for patients
to discuss with their physician. For example, for a
patient who was treated with a cholesterol-lowering
medication but had not achieved treatment goal,
their action plan would include a recommendation
to talk to their physician about optimizing their
cholesterol-lowering medication. Both the generic
and trade names of medications were indicated on
the reports.
Recommendations utilized in the computer-
generated algorithms were developed from the
NCEP, Healthy People 2000, the National Institutes
of Health Consensus Statement on Physical Activity
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and Cardiovascular Health and the Departments of
Agriculture and Health and Human Services’ Die-
tary Guidelines for Americans [28–32]. The tailored
messages were tested among patients for their
appropriateness.
After receipt of the personalized tools, interven-
tion patients received one phone call from a health
educator to discuss their personalized poster. This
phone call was designed to last no more than
10 min and strictly focused on and limited to dis-
cussion of the points on the patient’s poster. There
were no other educational, nutritional, or exercise
interventions. Patients were told to discuss issues
and questions regarding medication and dosing
with their primary physician.
Follow-up
Six months after enrollment, all patients were
mailed a follow-up letter and questionnaire.
Patients were then contacted to arrange for a
follow-up appointment. For patients who wanted
their testing carried out in their own physician’s
ofﬁce, arrangements were made for delivery and
pick-up of specimen kits. At close of the study, all
patients and their physicians received a letter with
their baseline and follow-up results. Patients in the
control group were mailed a personalized poster
and wallet card at the completion of the study.
Laboratory Analyses
All cholesterol proﬁles were performed at Penn
Medical Laboratory (Washington, DC). Blood for
laboratory measurements was collected by veni-
puncture after a ~12 h overnight fast. Total choles-
terol and HDL-C were measured enzymatically on
the Hitachi 717 autoanalyzer using reagents sup-
plied by the Roche Diagnostics Corporation (RDC,
Indianapolis, IN). Abel-Kendall analyzed serum,
purchased from North-west Lipid Research Labo-
ratory (NWLRL, Seattle, WA), and was used as the
calibrator. Controls included those supplied by
Roche and NWLRL. The laboratory participates in
the NWLRC lipid quality assurance program (Cho-
lesterol Standardization Certiﬁcation; RELABS).
LDL-C was measured directly in fresh plasma using
reagents from Sigma Diagnostics (St. Louis, MO).
Statistical Analysis
The power calculation was based on the assumption
of achieving a 10% reduction in LDL-C assuming
equal variance between the two groups. An estimate
of the standard deviation of 0.65 mmol/l (11.7 mg/
dL) was used and derived from the Scandinavian
Simvastatin Survival Study [33]. The experimental-
wise error rate is set at 0.05 (the test-based alpha is
0.025) and the Type II error rate is set at 0.2. An
assumption of a dropout rate of 10% per group was
based upon descriptions in behavioral interventions
[34]. Based on these assumptions, a sample size of
40 per group was projected to reach statistical sig-
niﬁcance using a Student’s t-test.
The major outcome variables were LDL-C and
total cholesterol. Differences between treatment
and control groups at baseline were assessed using
two-tailed unpaired t-tests. The changes observed
within each cohort were evaluated for signiﬁcant
differences between the pre- to postintervention
periods using a two-tailed paired t-test. The signif-
icance of the difference between the treatment and
control groups was evaluated by repeated measures
of analysis of variance that tested for changes
between the two groups from the pre to postinter-
vention periods. A P value of 0.05 was considered
statistically signiﬁcant.
Results
Of the 80 patients enrolled in the study, 35 were
randomized to receive the intervention and 45 to
the control group. There were no signiﬁcant differ-
ences between the two patient groups in baseline
age, education level, race, cholesterol levels, and
comorbidities (Table 1). We report the data on the
remaining patients in the intervention and the con-
trol group who completed the ﬁnal questionnaire
and returned for follow-up cholesterol testing.
After hospital discharge, there were one death in
the intervention group and three deaths in the con-
trol group, all attributed to CVD. One patient in
each group developed a chronic debilitating syn-
drome (cancer and amyolateral sclerosis); and seven
patients in the intervention group and four in the
control group declined further participation after
hospital discharge. Patients in the intervention
group were more likely than the controls to be male.
Patients in both groups had signiﬁcant prior
cardiac histories and did not differ with respect to
previous cardiac procedures (Table 1). There were
no differences in the percentage of patients in each
group who met their NCEP goal, with 34.6% of
intervention patients and 35.1% of controls having
a baseline LDL-C of <100 mg/dL, P = 0.21).
At the 6-month follow-up, there was a signiﬁcant
reduction in LDL-C and total cholesterol from base-
line concentrations in patients in the intervention
group and no changes in patients in the control
group (Table 2). A repeated measures analysis
between cohorts adjusting for baseline measures
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just failed to achieve a statistically signiﬁcant differ-
ence at the P = 0.05 level (P = 0.059).
These reductions did achieve signiﬁcance among
patients who had not met their NCEP goals at
baseline (Table 3). An evaluation on LDL-C dem-
onstrated a reduction in the intervention group
from 131.3 mg/dL to 109.8 mg/dL (-21.5 mg/dL)
whereas the change in the control group was from
137.2 mg/dL to 132.6 mg/dL (-4.6 mg/dL). The
repeated measures analysis demonstrated a statisti-
cally signiﬁcant difference between the control and
intervention groups on LDL-C after controlling for
baseline characteristics (P = 0.034).
At the 6-month follow-up of the entire cohort,
84.6% of intervention patients and 64.9% of con-
trol patients achieved an LDL-C of <130 mg/dL
(3.36 mmol/l), a standard now used by the National
Committee for Quality Assurance when evaluating
lipid control in a population with coronary heart
disease [35]. At baseline, fewer than 10% of
patients in each group knew the difference between
LDL-C (“lousy”) and HDL-C (“healthy”) choles-
terol at baseline, and all patients who did not know
difference were told at the time. Based on the fol-
low-up questionnaire, 61% (P = 0.001) of interven-
tion patients and 43% (P = 0.09) of control patients
Table 1 Patient characteristics at baseline
Control group (n = 37) Intervention group (n = 26) P value
Age (year, mean ± SD) 59.0 (±15.8) 62.5 (±9.1) 0.26
Male 57% 81% 0.02
Attended college 66.7% 53.8% 0.15
Race
White 78.4% 84.6% 0.20
African American 18.9% 11.5% 0.38
Other 2.7% 3.9% 0.44
Comorbidities*
Hypertension 42.3% 55.5% 0.15
Peripheral vascular disease 7.7% 0% 0.04
Previous procedures*
Catheterizations 2.7 (±2.8) 2.1 (±1.7) 0.15
Coronary bypass surgery 0.75 (1.1) 0.46 (0.7) 0.10
Angioplasty 1.27 (1.4) 1.11 (1.6) 0.34
LDL-C (mg/dL) [mmol/L] 117.8 (±35.9) [6.54] 114.2 (±30.4) [6.34] 0.34
Total cholesterol (mg/dL) [mmol/L] 181.2 (±39.9) [10.07] 187.2 (±29.3) [10.4] 0.25
*Events per patient, mean ± SD.
Table 2 Cholesterol concentrations at baseline and follow-up, all patients
Control group (n = 37) Intervention group (n = 26) 
Baseline Follow-up
Change 
within cohort P value Baseline Follow-up
Change
within cohort P value
LDL-C, mg/dL 
(mmol/l) 
[% change]
117.8 
(6.54)
116.7 
(6.48)
-1.1
(-0.06)
[1.0]
0.43 114.2 
(6.33)
101.8 
(5.65)
-12.4 
(0.69)
[10.9]
0.02
Total cholesterol,
mg/dL
(mmol/l) 
[% change]
181.2 
(10.07)
185.6 
(10.31)
+4.4
(0.22)
[2.42%]
0.24 187.2 
(10.4)
174.7 
(9.71)
-12.4 
(-0.69)
[6.62%]
0.02
Table 3 Cholesterol concentrations at baseline and follow-up, patients who did not meet NCEP goals at baseline
Control group (n = 24) Intervention group (n = 17) 
Baseline Follow-up
Change
within cohort P value Baseline Follow-up
Change 
within cohort P value
LDL-C, mg/dL 
(mmol/l) 
[% change]
137.2 
(7.62)
132.6 
(7.36)
[3.35%]
-4.6 
(-2.56)
0.28 131.3 
(7.29)
109.8 
(6.1)
-21.5
(-1.19)
[16.4%]
0.001
Total cholesterol,
mg/dL 
(mmol/l) 
[% change]
202.1 
(11.23)
200.5
(11.14)
-1.6 
(0.09)
0.43 199.0 
(11.06)
175.5 
(9.75)
-23.1 
(-1.28)
[11.6%]
0.001
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knew the difference between LDL-C and HDL-C at
the end of the study period.
Patients in the intervention group reported they
were more likely to talk to their physicians about
checking their cholesterol, starting an exercise pro-
gram, and improving blood pressure management.
They were more likely to know their LDL-C and
HDL-C goals. All of these follow-up outcomes
trended toward, but did not achieve statistical sig-
niﬁcance. During the study period, intervention
patients had fewer cardiac procedures as compared
with control patients (7.6% vs. 21.6%), but not at
levels that represent statistically meaningful differ-
ences that could be attributed to the study interven-
tion. All patients in the intervention group reported
that they kept their posters and wallet cards and
73% stated that they placed it on their refrigerator
or ﬁling cabinet and their poster remained up at the
close of the study.
Discussion
Putting prevention into practice is one of the three
major goals of Healthy People 2000, the national
health promotion and disease prevention objectives
of the US Department of Health and Human Serv-
ices [36]. We designed this intervention based upon
the hypothesis that shifting the locus of control
from the physician to the patient by providing
patients with their own written LDL-C status and
goals, could potentially improve outcomes.
We observed a reduction in LDL-C and total cho-
lesterol levels within the intervention group and a
more striking and signiﬁcant improvement among
patients with CVD who were not initially at their
NCEP goal. We attribute these ﬁndings in this pilot
study to the written status and goals, which were
delivered directly to patients and were a constant
visual reminder to patients and their families of
their status and the goals.
We learned from the Industrial Revolution that
performance and production among assembly line
workers were enhanced when individuals were
given feedback on their own production rate and
knew their goals [36]. These same theories of
enhancing task performance by involving patients
directly with their cholesterol status and goals, were
utilized in this study. Unlike providing generalized
knowledge on the subject of cholesterol and heart
disease, we allowed patients and their families to
have a benchmark of their own personal cholesterol
status and their goal. The posters were not thrown
away or ﬁled away in a drawer, and 73% of patients
kept the poster up on their refrigerator for the dura-
tion of the study. Patients commented that they
appreciated the simplicity of the reports, as well as
the inclusion of the names of pets and family mem-
bers who accompanied patients with their exercise
or activities.
Numerous studies have evaluated physicians’
practices and the impact of interventions aimed at
the health-care providers, yet there has been limited
study of patient interventions that may affect phy-
sician practice [37–40]. In this study, physicians
were blinded to which patients received interven-
tion tools, thus, we evaluated the impact of an inter-
vention placed solely in the hands of patients.
Enrollment and randomization occurred before
the availability of LDL-C results, thus, the inclusion
of patients who were at their LDL treatment goal at
baseline limited our ability to detect more sizable
changes within the entire cohort. Additionally,
study completion may have been enhanced had
enrollment been limited to those residing locally. All
of the patients who declined further participation
and follow-up after hospital discharge, resided out-
side of the immediate vicinity of the hospital.
Another limitation was sample size, which was
impacted by the funding resources available.
It was the objective of the researchers to help
patients feel that good health is achievable, to
strengthen their internal locus of control by empow-
ering patients with their own cholesterol status and
personalized written goals [41–43]. We embraced
the concepts delivered by Dr. James J. Putnam in
1899, that “medicine is not only the disease, but
also the man [44].” The investigators believe that
the greatest impact resulted from patients seeing
their own cholesterol status and goal, because few
even knew the difference between LDL-C and HDL-
C at baseline and none knew their individual LDL-
C levels.
Evaluating health-care outcomes is vital to effec-
tively close the gap between scientiﬁc advances and
the practice of medicine. Although we demon-
strated that this intervention could potentially have
a profound impact on short-term LDL-C outcomes,
the small sample size and selected population with
CVD limits the generalization of these results. Fur-
ther study is necessary to evaluate the long-term
beneﬁts and economic impact of tools such as the
ones we designed, not only among patients with
CVD, but also among patients at risk for CVD who
have not had a cardiac event.
Our data demonstrated that when patients with
CVD were given a personalized wall poster depict-
ing their cholesterol status and goals, their choles-
terol levels declined. The impact of having their
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individual levels and goals in front of them was
more effective than any known behavioral inter-
vention in lowering cholesterol in heart disease
patients. Further study is necessary to determine the
long-term implications of such interventions on
cholesterol levels and outcomes.
The software algorithm utilizes laboratory data
and patient data derived from a short questionnaire
that can be self-administered. The investigators
have developed a system to make these tools avail-
able to physician practices and managed care
populations with the cost of this intervention
approximating the cost of one dosage of a lipid-
lowering agent.
As we develop a strategic health plan for the 21st
century, the critical research that identiﬁes the
genetic, physiological, and environmental determi-
nants of disease must be accompanied by outcomes-
based research that evaluates how the scientiﬁc
advances can best be translated into cost-effective
and practical steps that patients can take to improve
their health. Not only must we ensure that patients
receive optimal medical care for an illness when it
strikes, but also ensure that patients understand the
important role that they themselves play in setting
and achieving their own health goals.
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